A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

Condition studied

Narcolepsy Type 2

Investigational medicinal product(s)

Eligibility

Primary endpoint

Change in Epworth Sleepiness Scale from baseline to Week 12 by dose level

Endpoint detail

Change in mean sleep latency on Maintenance of Wakefulness Test from baseline to Week 12 by dose level, Change in select patient-reported outcome measures from baseline to Week 12 by dose level.